Shots:

• The P-III OASIS-2 study involves assessing of Nuzyra (qd- PO) vs Linezolid (PO- bid) in 735 patients with acute bacterial skin and skin structure infections (ABSSSI)
• The P-III OASIS study results: met its 1EPs i.e- ECR rate (87.5% vs 82.5%); Clinical success rates at PTE in the mITT & CE population (84.2% & 97.9% vs 80.8% & 95.5%); efficacy profile is consistent with OASIS-1 study results- published in The Lancet Infectious Diseases
• Nuzyra is a novel antibiotic- comprising both IV & oral formulation- designed to overcome tetracycline resistance exhibiting broad-spectrum activity and has received FDA’s approval for CABP and ABSSSI in adults on Oct 02- 2019

Click here to­ read full press release/ article | Ref: Paratek | Image: The Pharma Letter